241 related articles for article (PubMed ID: 17277001)
1. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Papapoulos SE; Schimmer RC
Ann Rheum Dis; 2007 Jul; 66(7):853-8. PubMed ID: 17277001
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Papapoulos SE; Schimmer RC
Postgrad Med J; 2008 Jun; 84(992):307-12. PubMed ID: 18644921
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
4. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Reginster JY
Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
[TBL] [Abstract][Full Text] [Related]
5. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
6. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
7. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
8. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
9. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
10. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
11. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
[TBL] [Abstract][Full Text] [Related]
14. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
15. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Epstein S
Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
[TBL] [Abstract][Full Text] [Related]
17. Quarterly intravenous ibandronate for postmenopausal osteoporosis.
Emkey RD
Womens Health (Lond); 2008 May; 4(3):219-28. PubMed ID: 19072470
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate: is there an effect on nonvertebral fractures?
Kastelan D; Korsic M; Vlak T
Clin Rheumatol; 2008 Oct; 27(10):1313-5. PubMed ID: 18651099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]